283 related articles for article (PubMed ID: 27834733)
1. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
[TBL] [Abstract][Full Text] [Related]
2. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Mohamed E; Kumar A; Zhang Y; Wang AS; Chen K; Lim Y; Shai A; Taylor JW; Clarke J; Hilz S; Berger MS; Solomon DA; Costello JF; Molinaro AM; Phillips JJ
Neuro Oncol; 2022 Sep; 24(9):1471-1481. PubMed ID: 35287169
[TBL] [Abstract][Full Text] [Related]
4. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
6. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Lai A; Kharbanda S; Pope WB; Tran A; Solis OE; Peale F; Forrest WF; Pujara K; Carrillo JA; Pandita A; Ellingson BM; Bowers CW; Soriano RH; Schmidt NO; Mohan S; Yong WH; Seshagiri S; Modrusan Z; Jiang Z; Aldape KD; Mischel PS; Liau LM; Escovedo CJ; Chen W; Nghiemphu PL; James CD; Prados MD; Westphal M; Lamszus K; Cloughesy T; Phillips HS
J Clin Oncol; 2011 Dec; 29(34):4482-90. PubMed ID: 22025148
[TBL] [Abstract][Full Text] [Related]
7. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.
Avliyakulov NK; Rajavel KS; Le KM; Guo L; Mirsadraei L; Yong WH; Liau LM; Li S; Lai A; Nghiemphu PL; Cloughesy TF; Linetsky M; Haykinson MJ; Pope WB
J Neurooncol; 2014 Mar; 117(1):53-65. PubMed ID: 24473683
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
9. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
[TBL] [Abstract][Full Text] [Related]
10. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
[TBL] [Abstract][Full Text] [Related]
11. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
12. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S
Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483
[TBL] [Abstract][Full Text] [Related]
13. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
[TBL] [Abstract][Full Text] [Related]
14. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
17. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Birner P; Pusch S; Christov C; Mihaylova S; Toumangelova-Uzeir K; Natchev S; Schoppmann SF; Tchorbanov A; Streubel B; Tuettenberg J; Guentchev M
Cancer; 2014 Aug; 120(16):2440-7. PubMed ID: 24771584
[TBL] [Abstract][Full Text] [Related]
19. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
20. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Vitucci M; Karpinich NO; Bash RE; Werneke AM; Schmid RS; White KK; McNeill RS; Huff B; Wang S; Van Dyke T; Miller CR
Neuro Oncol; 2013 Oct; 15(10):1317-29. PubMed ID: 23814263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
